Single-dose amikacin plus 7 days of amoxicillin/clavulanate to treat acute cystitis caused by extended-spectrum beta-lactamase-producing Escherichia coli: A retrospective cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Sun Tae | - |
dc.contributor.author | Han, Da Eun | - |
dc.contributor.author | Lee, Dong Hyun | - |
dc.contributor.author | Kim, Jong Wook | - |
dc.contributor.author | Park, Hong Seok | - |
dc.contributor.author | Moon, Du Geon | - |
dc.contributor.author | Oh, Mi Mi | - |
dc.date.accessioned | 2021-11-20T19:40:43Z | - |
dc.date.available | 2021-11-20T19:40:43Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 2466-0493 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/128150 | - |
dc.description.abstract | Purpose: Treatment options for urinary tract infection (UTI) caused by extended-spectrum beta-lactamase (ESBL)-producing organisms are limited other than carbapenem. Accordingly, clinicians should investigate alternative antimicrobial options for limited infection. This study was performed to assess the efficacy of single-dose amikacin and a 7-day oral regimen of amoxicillin/clavulanate for the treatment of acute cystitis caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae. Materials and Methods: A single-dose amikacin and 7-day oral amoxicillin/clavulanate regimen was given to all patients with acute cystitis or recurrent cystitis between May 2016 and October 2018. We conducted a retrospective cohort study assessing the efficacy of this regimen for the treatment of UTI due to ESBL-producing organisms. Both clinical and laboratory efficacy were assessed a minimum of 7 days and a maximum of 14 days after the completion of treatment. Results: A total of 47 patients were enrolled in this study. E. coli and K. pneumoniae were isolated in 44 patients (93.6%) and 3 patients (6.4%), respectively. Of the 47 enrolled, 39 patients (83.0%) showed sterile culture results on follow-up. Thirty-seven patients (78.7%) showed improvement of symptoms. Of 8 patients who showed bacterial persistence, 4 patients showed ESBL-producing E. coli, whereas 4 patients showed non-ESBL E. coli on follow-up cultures. During follow-up, 12 patients experienced the recurrence of acute cystitis with a median recurrence period of 2.5 months. Conclusions: The combination of amoxicillin/clavulanate and amikacin may be an alternative to carbapenem treatment in patients with acute cystitis caused by ESBL-producing Enterobacteriaceae. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN UROLOGICAL ASSOC | - |
dc.title | Single-dose amikacin plus 7 days of amoxicillin/clavulanate to treat acute cystitis caused by extended-spectrum beta-lactamase-producing Escherichia coli: A retrospective cohort study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jong Wook | - |
dc.contributor.affiliatedAuthor | Park, Hong Seok | - |
dc.contributor.affiliatedAuthor | Moon, Du Geon | - |
dc.contributor.affiliatedAuthor | Oh, Mi Mi | - |
dc.identifier.doi | 10.4111/icu.20200240 | - |
dc.identifier.scopusid | 2-s2.0-85105316438 | - |
dc.identifier.wosid | 000652239000010 | - |
dc.identifier.bibliographicCitation | INVESTIGATIVE AND CLINICAL UROLOGY, v.62, no.3, pp.310 - 316 | - |
dc.relation.isPartOf | INVESTIGATIVE AND CLINICAL UROLOGY | - |
dc.citation.title | INVESTIGATIVE AND CLINICAL UROLOGY | - |
dc.citation.volume | 62 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 310 | - |
dc.citation.endPage | 316 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002714614 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.subject.keywordPlus | CARBAPENEM-RESISTANT ENTEROBACTERIACEAE | - |
dc.subject.keywordPlus | GRAM-NEGATIVE BACILLI | - |
dc.subject.keywordPlus | PIPERACILLIN-TAZOBACTAM | - |
dc.subject.keywordPlus | AMOXICILLIN-CLAVULANATE | - |
dc.subject.keywordPlus | KLEBSIELLA-PNEUMONIAE | - |
dc.subject.keywordPlus | BACTEREMIA | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | FOSFOMYCIN | - |
dc.subject.keywordPlus | SUSCEPTIBILITY | - |
dc.subject.keywordPlus | NITROFURANTOIN | - |
dc.subject.keywordAuthor | Amikacin | - |
dc.subject.keywordAuthor | Amoxi-clavulanate | - |
dc.subject.keywordAuthor | Cystitis | - |
dc.subject.keywordAuthor | Escherichia coli | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.